Back to discover
Drug

Eptifibatide

Approved · EMA
Emerging researchLate-stage development

Also known as Integrilin, Eptifibatida.

RxNorm75635ChEMBLCHEMBL1174UNIINA8320J834
2
Research papers
1
Active clinical trials
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Efficacy and Safety of Eptifibatide Therapy Following Intravenous Thrombolysis in Acute Ischemic Stroke Patients Within 4.5 to 24 Hours After Onset: A Multicenter, Randomized Controlled Trial

Clinical trial2026-01-16Results expected Q3 2029 · ClinicalTrials.gov

Market withdrawal: Integrilin (EMA)

Regulatory2026-01-01EMA

Multi-arm Optimization of Stroke Thrombolysis (MOST): a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic Stroke

Clinical trial2025-02-07Results posted · ClinicalTrials.gov

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)

Clinical trial2024-05-17Results posted · ClinicalTrials.gov

A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention

Clinical trial2021-05-13Results posted · ClinicalTrials.gov

Safety and Efficacy of Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke: a Single-arm, Open-label, Multicenter Clinical Trial

Clinical trial2020-06-30Primary completion · ClinicalTrials.gov

The Effects of Crushed Ticagrelor Versus Eptifibatide Bolus +Clopidogrel in Troponin-Negative ACS Patients Undergoing Coronary Intervention

Clinical trial2020-05-04Results posted · ClinicalTrials.gov

Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention

Clinical trial2017-02-28Results posted · ClinicalTrials.gov

Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)

Clinical trial2016-01-21Results posted · ClinicalTrials.gov

Approval: Eptifibatide Accord (EMA)

Regulatory2016-01-11EMA

Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.

Research2015-08-04Stroke

Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.

Research2009-03-01Journal of the American College of Cardiology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Eptifibatide
Aliases & brands
IntegrilinEptifibatida
RxNorm CUI
75635
ChEMBL ID
CHEMBL1174
UNII
NA8320J834
Regulatory jurisdictions
ema

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2016-01-11
Latest approval
2016-01-11
Authorities
EMA
Total events
2
emaEuropean Medicines Agency· 2 events
2026-01-01Market withdrawalMarket
Market withdrawal: Integrilin (EMA)
Indication: Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients… Show full indication

Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes. Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).

Evidence ↗
2016-01-11Approval
Approval: Eptifibatide Accord (EMA)
Indication: Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin. Eptifibatide Accord is indicated for the prevention of early myocardial infarction in… Show full indication

Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin. Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes. Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

22 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
22
registered trials across all phases
LATEST COMPLETION 2024
1
Active studies
1
Recruiting
11
Late-stage (III+)
15
Completed
6
Discontinued
PHASE DISTRIBUTIONn = 22
Phase 1 / 22Phase 29Phase 37Phase 44

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

CompletedPH IVMedical University of Silesian=1402010

A RANDOMIZED TRIAL COMPARING EPTIFIBATIDE AND PLACEBO IN PATIENTS WITH DIFFUSE CORONARY DISEASE UNDERGOING DRUG-ELUTING STENTING

TerminatedPH IVUniversity of Turin, Italyn=912009

Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance

TerminatedPH IVKey trialBrigham and Women's Hospitaln=1,2002007

Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

CompletedPH IVCardiology Research UBCn=6242007

Efficacy and Safety of Eptifibatide Therapy Following Intravenous Thrombolysis in Acute Ischemic Stroke Patients Within 4.5 to 24 Hours After Onset: A Multicenter, Randomized Controlled Trial

Not yet recruitingPH IIIXinqiao Hospital of Chongqingn=7862029

Recent completions

Trials that read out recently, adding to the completed evidence base.

Multi-arm Optimization of Stroke Thrombolysis (MOST): a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic Stroke

CompletedPH IIIWashington University School of Medicinen=5142024

A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention

CompletedPH IIMedicuren=5352019

The Effects of Crushed Ticagrelor Versus Eptifibatide Bolus +Clopidogrel in Troponin-Negative ACS Patients Undergoing Coronary Intervention

CompletedPH IIUniversity of Alabama at Birminghamn=1002018

Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention

CompletedPH IIUniversity of Alabama at Birminghamn=702015

Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)

CompletedPH IIArthur Panciolin=272015

Randomized, Double-blind, Triple-dummy Trial to Compare the Efficacy of Otamixaban With Unfractionated Heparin + Eptifibatide, in Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy

CompletedPH IIIKey trialSanofin=13,2202013

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20092015
Major research themes2
Angioplasty, Balloon, Coronary1Stents1
Journals, researchers & institutions
Top journals
  • Journal of the American College of Cardiology1
  • Stroke1
Leading researchers
  • Adeoye O1
  • Aymong E1
  • Broderick JP1
  • Buller CE1
  • Carere RG1
  • Demel S1
  • Densem C1
  • Eckerle B1
Leading institutions
free-text, unnormalised
  • From the University of Cincinnati Neuroscience Institute1
  • Vancouver General Hospital1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.